Etanercept-SZZS(Sandoz Inc.)

DUBLIN, March 14, 2024 /PRNewswire/ -- The "Psoriasis in America 2023: Understanding the Psoriasis Patient Experience" report has been added to ResearchAndMarkets.com's offering. Approximately 7.5 million people in the United States have psoriasis. This Psoriasis in America report provides a comprehensive look at life for those living with psoriasis. Using detailed quantitative data, it gives a full picture of the psoriasis patient experience - from symptoms to treatment to HCP relationships to quality of life - so you can make informed, strategic decisions, identify opportunities, and understand potential challenges. The report offers an in-depth look at the psoriasis patient experience. This large-scale, patient-reported data leverages vital quantitative insights essential to understanding key touchpoints in the psoriasis patient journey, including condition management, HCP engagement, quality of life, treatment experience and satisfaction, and much more. This report lifts the curtain on life with psoriasis, giving stakeholders an actionable look at the behaviors, attitudes, perceptions, needs, and experiences of people living with the condition. Data can be used to inform strategic decisions, including product communications, competitive assessments, concept development, landscape analyses, patient journey overlays, and forecasting inputs. This report also addresses important questions that stakeholders may not even know to ask while offering valuable insights into must-have patient-reported data points not available anywhere else. Add-on custom data analysis opportunities are also available for an additional cost - please see the report following purchase for more information. The analyst reaches millions of people through its portfolio of 45+ condition-specific online health communities - including PlaquePsoriasis.com - to provide information, connection, and support to patients and caregivers in the U.S. This report includes a deep-dive into: Psoriasis patient demographics Age, gender, ethnicity, marital status, children, employment status, income, location, insurance, and other health conditions Impact of psoriasis on quality of life Severity, impact on quality of life, symptoms experienced, and what patients wish others better understood Information-seeking behaviors Information sources used, plus topics of interest HCP engagement Primary HCP seen for condition, satisfaction with HCP, and discussion about brands aware of/not used Psoriasis treatment awareness and experiences Aided awareness of specific treatments, treatment experience, satisfaction with current treatments, perceived control with current treatment plan, and interest/participation in clinical trials Key questions answered in this report: To what extent do people say psoriasis impacts their overall quality of life? What's the average number of flares in the past year? What do patients wish others understood about psoriasis? What percentage of patients see a specialist for psoriasis treatment? What treatments have the highest aided brand awareness among patients? What percentage of patients use a biologic? How many patients feel their psoriasis is well-controlled on their current treatment plan? What percentage of patients are likely to switch or add new treatments in the next six months? What medications have patients discussed with their HCP? What are the top online resources people with psoriasis use to find information? What kinds of content and information do patients search for? What percentage of patients search for information on treatment options? Methodology Psoriasis in America consists of: A 20-minute online quantitative survey, covering demographics, comorbidities, quality of life/impact, HCP interactions, as well as treatment awareness, experiences, and discussions Qualitative patient insights from open-ended responses Additional details: Fielded: January 16, 2023 to April 14, 2023 Convenience sample of 490 respondents diagnosed with psoriasis Respondents are age 18+, living in the U.S., and are recruited from proprietary online health communities and recruiting partners Key Topics Covered: Respondent Demographics Research Highlights Condition Status and Quality of Life Severity and Exacerbations Symptoms Experienced Impact on Quality of Life Qualitative Patient Insights Information-Seeking Behaviors Resources Used to Manage Health Types of Content/Information Sought Treatment Awareness and Experiences Primary HCP Seen for Psoriasis Care Aided Brand Awareness of Treatments Treatment Usage Condition Control on Current Treatment and Clinical Trial Interest Treatment Discussions with HCP Appendix with All Data Charts and Distributions Brands and treatments mentioned in this report include: Topical corticosteroid (such as hydrocortisone) BRYHALIT (halobetasol propionate) lotion DesOwen (desonide) SERNIVOT (betamethasone dipropionate) SORILUXT Foam (calcipotriene) TACLONEX (calcipotriene and betamethasone) TAZORAC (tazarotene) VECTICAL (calcitriol) VTAMA (tapinarof) ZITHRANOLT-RR (anthralin) ZORYVET (roflumilast) Acitretin (SORIATANE) ARAVA (leflunomide) Azathioprine (such as IMURAN, AZASAN) Cyclosporine (such as Sandimmune, NEORAL, RESTASIS) Methotrexate (eg, Rheumatrex), also sometimes given as an injection OTEZLA (apremilast) PLAQUENIL (hydroxychloroquine) RINVOQ (upadacitinib) SOTYKTUT (deucravacitinib) Sulfasalazine (Azulfidine) XELJANZ/XELJANZ XR (tofacitinib citrate) AMJEVITAT (adalimumab-atto) Hide until launched in US AVSOLA (infliximab-axxq) CIMZIA (certolizumab) COSENTYX (secukinumab) CYLTEZO (adalimumab-adbm) Hide until launched in US ENBREL (etanercept) ERELZIT (etanercept-szzs) Hide until launched in US HULIO (adalimumab-fkjp) Hide until launched in US HUMIRA (adalimumab) HYRIMOZ (adalimumab-adaz) Hide until launched in US ILUMYAT (tildrakizumab-asmn) INFLECTRA (infliximab-dyyb) IXIFIT (infliximab-qbtx) Hide until launched in US ORENCIA (abatacept) REMICADE (infliximab) RENFLEXIST (infliximab-abda) SIMPONI (golimumab) SIMPONI ARIA (golimumab for infusion) SILIQT (brodalumab) SKYRIZI (risankizumab-rzaa) STELARA (ustekinumab) TALTZ (ixekizumab) TREMFYA (guselkumab) For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

Pictured: Sign at the Department of Health and Human Services' office in Washington, DC/iStock, JHVEPhoto The Department of Health and Human Services announced Thursday that it sent initial proposals to pharma companies, kicking off a months-long process to settle on a maximum fair price for the 10 drugs selected for negotiations under the Inflation Reduction Act. The Centers for Medicare and Medicaid Services is conducting these negotiations and participating drugmakers have 30 days to either signify that they agree with the proposed pricing or submit a counteroffer. At a JPM Week event last month, life sciences lobbying group Incubate predicted that all 10 companies would challenge CMS’s initial offer, particularly as the Biden administration is expected to make “draconian” price cuts amid the political pressure of the presidential election year. Analysts agreed this week, telling Reuters that they expect that CMS would propose steep discounts in their initial offer, ranging from a statutory price cut minimum of 25% and reaching as high as 60%. Negotiations will take place through the spring and summer and are scheduled to end on Aug. 1, according to a CMS fact sheet. The agency has until Sept. 1 to publish the final negotiated maximum fair prices for the 10 selected drugs, which will then take effect in 2026. “Allowing Medicare to negotiate drug prices is just one tool we’re using to lower prices thanks to the President’s lower cost prescription drug law,” HHS Secretary Xavier Becerra said in a statement. “From capping insulin at $35 per month, to making drug companies pay a rebate for raising their prices faster than inflation, to capping out of pocket costs in Part D, we are delivering on that day-one promise.” However, the Pharmaceutical Research and Manufacturers of America (PhRMA) on Thursday said in a statement CMS’s initial price-setting “offer” to companies was an effort to “win political points on the campaign trail.” PhRMA also criticized the negotiations process for its lack of transparency and “operating behind closed doors to set medicine prices without disclosing for months how they arrived at the price or how much patient and provider input was used.” The Inflation Reduction Act (IRA) was signed into law in August 2022, as part of the Biden administration’s effort to generate some $25 billion in drug cost savings annually by 2031. To help achieve this goal, the IRA allows CMS to negotiate prices for some of the most widely prescribed medicines. The first 10 drugs that would be impacted by these negotiations were named in August 2023 and include BMS’s Eliquis (apixaban), Novartis’ Entresto (sacubitril/valsartan), Amgen’s Enbrel (etanercept), Lilly’s Jardiance (empagliflozin), AstraZeneca’s Farxiga (dapagliflozin), Merck’s Januvia (sitagliptin), Novo Nordisk’s insulin products Fiasp and Novolog and J&J’s Xarelto (rivaroxaban), Imbruvica (ibrutinib) and Stelara (ustekinumab). HHS on Thursday also released data from several reports showing the disparity in drug prices between the U.S. and other countries in the Organization for Economic Cooperation and Development (OECD). The findings show that in 2022 prices across all drugs in the U.S. were nearly three times as high as prices in 33 OECD countries, with American consumers paying $2.78 per dollar paid in those other countries for medicines. The gap is even larger for insulin, which was nearly 10 times more expensive in the U.S. than in the 33 countries. Tristan Manalac is an independent science writer based in Metro Manila, Philippines. Reach out to him on LinkedIn or email him at tristan@tristanmanalac.com or tristan.manalac@biospace.com.